Effects of immunomodulators on liquefaction and ulceration in the rabbit skin model of tuberculosis

Tuberculosis
Hongjia SunBingdong Zhu

Abstract

To better control tuberculosis (TB) epidemics in developing countries a real need exists to study the liquefaction and cavity formation that occur in pulmonary TB lesions. This report is the first to evaluate the effects of immunomodulators on these two processes in a rabbit skin model. The effects of recombinant human interferon-γ (rIFN-γ), recombinant human interleukin-2 (rIL-2), dexamethasone and cyclophosphamide (CTX) were evaluated in TB lesions produced by intradermal injection of 5 × 10(6) viable BCG bacilli. Recombinant IL-2 and rIFN-γ accelerated the liquefaction and healing of the lesions, and reduced the bacterial load. In contrast, dexamethasone inhibited the liquefaction of the lesions, and increased the bacterial load. The effect of CTX was similar to dexamethasone but not as pronounced. Serum levels of IL-2 were higher during the liquefaction and healing phases in the rIL-2 and rIFN-γ groups. Therefore, immunomodulators affect both the development of TB lesions and the survival of the mycobacteria within them. This study suggests that the rabbit skin model can be a valuable method to select therapeutic agents that could inhibit liquefaction and cavity formation in pulmonary tuberculosis.

References

Mar 1, 1989·Reviews of Infectious Diseases·A M Dannenberg
Jun 1, 1985·Cellular Immunology·D KabelitzH Wagner
Oct 1, 1987·The Journal of Physiology·A MorimotoT Watanabe
Jun 24, 1999·Immunology Today·I M Orme, A M Cooper
Mar 22, 2002·Nature Reviews. Immunology·S H Kaufmann
Jul 17, 1953·Annals of the New York Academy of Sciences·M B LURIEE CARDONA-LYNCH
Apr 29, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L AaronO Lortholary
Dec 20, 2005·Tuberculosis·Kris L HelkeYukari C Manabe
Mar 21, 2006·Lancet·Christopher Dye
Jan 11, 2007·Immunology and Cell Biology·Bernadette M Saunders, Warwick J Britton
Dec 7, 2007·EMBO Reports·Martin F Bachmann, Annette Oxenius
Aug 13, 2009·European Journal of Immunology·Douglas Young
Feb 16, 2010·Immunity·Gabrielle T Belz, Frédérick Masson
Apr 27, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Keertan DhedaYing Zhang
Oct 12, 2010·Clinical Microbiology Reviews·Arthur M Dannenberg
Mar 26, 2011·Clinical & Developmental Immunology·Pere-Joan Cardona

❮ Previous
Next ❯

Citations

Oct 9, 2014·FEMS Microbiology Letters·Lingjun ZhanChuan Qin
Jan 18, 2018·Respirology : Official Journal of the Asian Pacific Society of Respirology·Bingdong ZhuYing Zhang
Feb 16, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Junli LiChuan Qin
May 20, 2017·Frontiers in Microbiology·Lingjun ZhanChuan Qin
Jun 2, 2017·Frontiers in Microbiology·Huiyu ChenYing Zhang
Jul 13, 2019·Microbiology Spectrum·Jonathan Kevin Sia, Jyothi Rengarajan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.